MASH (Metabolic Dysfunction-Associated Steatohepatitis)

Rezdiffra: First FDA-Approved Drug for Treating Fatty Liver Disease

The FDA has approved resmetitron (brand name Rezdiffra) for adult patients with moderate to advanced scarring of the liver due to fatty liver disease.

Mar 26th, 2024

Resmetirom In Line to Become First Medication-Based Treatment for MASH

Feb 19th, 2024

What is resmetirom and how might it help treat this liver disease – MASH – metabolic dysfunction-associated steatohepatitis?

MASH (Metabolic Dysfunction-Associated Steatohepatitis)

Rezdiffra: First FDA-Approved Drug for Treating Fatty Liver Disease

Resmetirom In Line to Become First Medication-Based Treatment for MASH

Categories

Includes These Must Reads:

Thank You!